Premium
Detection of centrosome amplification as a surrogate marker of dysfunction in the p53 pathway – p53 gene mutation or MDM2 overexpression
Author(s) -
Kaneko N.,
Okuda M.,
Toyama N.,
Oikawa T.,
Watanabe M.,
Kanaya N.,
Yazawa M.,
Hasegawa K.,
Morimoto M.,
Hayashi T.,
Une S.,
Nakaichi M.,
Taura Y.,
Tsujimoto H.,
Inokuma H.
Publication year - 2005
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/j.1476-5810.2005.00080.x
Subject(s) - centrosome , biology , mutation , mdm2 , gene , cancer research , gene mutation , microbiology and biotechnology , genetics , cell cycle
In human and canine cancers, the inactivation of p53 protein as well as p53 gene mutation and MDM2 overexpression result in centrosome amplification that in turn contributes to chromosomal instability. To explore the usefulness of the detection of centrosome amplification as a surrogate marker of dysfunction in the p53 pathway, we systematically analysed centrosome amplification, p53 overexpression, p53 gene mutation and MDM2 overexpression in canine tumours. Centrosome amplification was detected in 16 of 51 (31%) naturally developing tumours in dogs. All the tumour specimens with aberrations in the p53 pathway, including p53 overexpression, p53 gene mutation or MDM2 overexpression, showed centrosome amplification, suggesting that the detection of centrosome amplification could serve as a preliminary surrogate marker of dysfunction in the p53 pathway.